TL Foundation Backs VETmAb BIO's Serial Local Entrepreneurs to Strengthen San Diego's Economic Future
Source: PR NewswireView original on PR Newswire
Investment helps accelerate growth for an accomplished vet biotech team advancing new treatments for pets worldwide
SAN DIEGO, Nov. 17, 2026 /PRNewswire/ -- TL Foundation has invested in VETmAb Biosciences (VETmAb BIO), backing second-time San Diego veterinary biotechnology founders now developing monoclonal antibody therapies for chronic and debilitating diseases affecting dogs and cats.
Led by co-founder and CEO Denise Bevers, VETmAb BIO founding team built Kindred Biosciences on the same model, which led to four veterinary FDA product approvals and a $440 million acquisition by Elanco Animal Health.
Their decision to launch another company in San Diego reflects the cycle TL seeks to strengthen, where accomplished entrepreneurs bring their expertise and experience to new ventures that benefit the region's economic growth.
"Our primary ambition is to build another successful company that brings life-changing medicines to pets and the families who love them," Bevers said. "Through our partnership with TL Foundation, we also have the chance to contribute to something bigger, creating resources and opportunities for future generations of San Diego entrepreneurs."
TL's investment, alongside funding from other investors, will help accelerate critical research and development milestones as VETmAb BIO advances its treatments. As the company grows, it has the potential to expand San Diego's expertise in veterinary biotechnology, attract outside capital, create specialized jobs and increase demand for laboratory and office space, benefiting local businesses and the broader economy.
"Denise and her team represent what's so powerful about San Diego," said Kris Lichter, CEO of TL Foundation. "They're experienced local founders recommitting to the very space and community they know so well. They understand the need, the science and how to build a well-run operation here to make it happen."
TL's relationships across the business and philanthropic community help identify promising companies and connect them with capital. Early funding from San Diego leaders, including Andy Ballester, Malin Burnham and Buzz Woolley, has helped advance its mission. Its portfolio investments also include Condor Software, Looq, Papillon Therapeutics, Resolute Science, Proper Voltage and Welby Health.
As a 501(c)(3) nonprofit philanthropic venture fund, TL reinvests 100 percent of its investment returns, with no management fees or carried interest, designed to create a lasting source of capital for future San Diego startups. Each investment helps expand the region's capacity to innovate globally with the potential to generate returns and strengthen San Diego's economic resilience and self-reliance.
TL invites individuals and organizations to participate through tax-deductible contributions, including donor-advised fund grants and stock donations, with no minimum gift.
Learn more at SanDiegoTLF.org or contact [email protected].
Media Contact:
Michele Moninger
858-450-9872
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/tl-foundation-backs-vetmab-bios-serial-local-entrepreneurs-to-strengthen-san-diegos-economic-future-302942109.html
Source: PR NewswireView original on PR Newswire
Content provided by PR Newswire. Redistribution, resale or sublicensing is not permitted.